DeepSyte matches this bill to the issues you care about and shows whether your reps' votes line up — not party, not press releases. Take the 2-minute values quiz to see your alignment.
Sign in and take the values quiz to see how this bill lines up with what you've said.
The Fairness for Patient Medications Act establishes protections for patients using drugs that receive substantial manufacturer rebates. It requires the Secretary of Health and Human Services to identify 'highly rebated drugs'—those where rebates and price reductions exceed 50% of total annual spending—and caps patient cost-sharing for these drugs at one-twelfth of the plan's annual net price per 30-day supply, effective January 1, 2025. The bill also requires that when plans newly cover a previously excluded highly rebated drug, any manufacturer rebates must either be reflected at the point of sale to patients or take the form of flat fees unrelated to sales volume.
Sign in and take the values quiz to get a personalized read on how this bill lines up with your positions.
Sign in to see how your representatives voted on this bill.